The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Poncina, Nicol ^a   Albiero, Mattia ^a   Menegazzo, Lisa ^a   Cappellari, Roberta ^a   Avogaro, Angelo ^a   Fadini, Gian P ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Angiogenesis; Cardiovascular disease; Regeneration; Stem cells

Indexed keywords

SAXAGLIPTIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DIABETIC PATIENT; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; PROANGIOGENIC CELL; PROGENY;

ADAMANTANE; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84901503431     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-92     Document Type: Article

References (38)

1. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011, 34(Suppl 2):S285-S290. 3632194, 21525470.
2. Fadini GP. A reappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications. Diabetologia 2014, 57(1):4-15. 10.1007/s00125-013-3087-6, 24173366.
3. Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, Vigili de Kreutzenberg S, Tiengo A, Agostini C, Avogaro A. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006, 26(9):2140-2146. 10.1161/01.ATV.0000237750.44469.88, 16857948.
4. Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M. Advanced glycation end products impair the migration, adhesion and secretion potentials of late endothelial progenitor cells. Cardiovasc Diabetol 2012, 11:46. 10.1186/1475-2840-11-46, 3403843, 22545734.
5. Keats EC, Khan ZA. Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise. Cardiovasc Diabetol 2012, 11:37. 10.1186/1475-2840-11-37, 3476432, 22524626.
6. Zhao CT, Wang M, Siu CW, Hou YL, Wang T, Tse HF, Yiu KH. Myocardial dysfunction in patients with type 2 diabetes mellitus: role of endothelial progenitor cells and oxidative stress. Cardiovasc Diabetol 2012, 11:147. 10.1186/1475-2840-11-147, 3537556, 23217199.
7. Fadini GP, Albiero M, Vigili de Kreutzenberg S, Boscaro E, Cappellari R, Marescotti M, Poncina N, Agostini C, Avogaro A. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013, 36(4):943-949. 10.2337/dc12-1084, 3609511, 23111057.
8. Menegazzo L, Albiero M, Avogaro A, Fadini GP. Endothelial progenitor cells in diabetes mellitus. Biofactors 2012, 38(3):194-202. 10.1002/biof.1016, 22488933.
9. Fadini GP, Avogaro A. Potential manipulation of endothelial progenitor cells in diabetes and its complications. Diabetes Obes Metab 2010, 12(7):570-583. 10.1111/j.1463-1326.2010.01210.x, 20590732.
10. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 2012, 110(4):624-637. 10.1161/CIRCRESAHA.111.243386, 3382070, 22343557.
11. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33(2):187-215. 10.1210/er.2011-1052, 3528785, 22323472.
12. Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011, 55(1-3):10-16.
13. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10(8):858-864. 10.1038/nm1075, 15235597.
14. Zheng H, Fu G, Dai T, Huang H. Migration of endothelial progenitor cells mediated by stromal cell-derived factor-1alpha/CXCR4 via PI3K/Akt/eNOS signal transduction pathway. J Cardiovasc Pharmacol 2007, 50(3):274-280. 10.1097/FJC.0b013e318093ec8f, 17878755.
15. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33(7):1607-1609. 10.2337/dc10-0187, 2890368, 20357375.
16. Huang CY, Shih CM, Tsao NW, Lin YW, Huang PH, Wu SC, Lee AW, Kao YT, Chang NC, Nakagami H, Morishita R, Ou KL, Hou WC, Lin CY, Shyu KG, Lin FY. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br J Pharmacol 2012, 167(7):1506-1519. 10.1111/j.1476-5381.2012.02102.x, 3514763, 22788747.
17. Shih CM, Chen YH, Lin YW, Tsao NW, Wu SC, Kao YT, Chiang KH, Li CY, Chang NC, Lin CY, Huang CY, Lin FY. MK-0626, A Dipeptidyl Peptidase-4 Inhibitor, Improves Neovascularization by Increasing Both the Number of Circulating Endothelial Progenitor Cells and Endothelial Nitric Oxide Synthetase Expression. Curr Med Chem 2014, 21(17):2012-2022. 10.2174/09298673113206660273, 24059225.
18. Hur J, Yang HM, Yoon CH, Lee CS, Park KW, Kim JH, Kim TY, Kim JY, Kang HJ, Chae IH, Oh BH, Park YB, Kim HS. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation 2007, 116(15):1671-1682. 10.1161/CIRCULATIONAHA.107.694778, 17909106.
19. Chen X. Biochemical properties of recombinant prolyl dipeptidases DPP-IV and DPP8. Adv Exp Med Biol 2006, 575:27-32. 10.1007/0-387-32824-6_3, 16700505.
20. Fadini GP, Albiero M, Seeger F, Poncina N, Menegazzo L, Angelini A, Castellani C, Thiene G, Agostini C, Cappellari R, Boscaro E, Zeiher A, Dimmeler S, Avogaro A. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Basic Res Cardiol 2013, 108(1):313.
21. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes Metab 2012, 14(6):518-522. 10.1111/j.1463-1326.2011.01550.x, 22171692.
22. Broxmeyer HE, Hoggatt J, O'Leary HA, Mantel C, Chitteti BR, Cooper S, Messina-Graham S, Hangoc G, Farag S, Rohrabaugh SL, Ou X, Speth J, Pelus LM, Srour EF, Campbell TB. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med 2012, 18(12):1786-1796. 10.1038/nm.2991, 3742313, 23160239.
23. Spinetti G, Fortunato O, Cordella D, Portararo P, Krankel N, Katare R, Sala-Newby GB, Richer C, Vincent MP, Alhenc-Gelas F, Tonolo G, Cherchi S, Emanueli C, Madeddu P. Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ Res 2011, 108(3):284-293. 10.1161/CIRCRESAHA.110.236786, 3596779, 21164105.
24. Wara AK, Croce K, Foo S, Sun X, Icli B, Tesmenitsky Y, Esen F, Rosenzweig A, Feinberg MW. Bone marrow-derived CMPs and GMPs represent highly functional proangiogenic cells: implications for ischemic cardiovascular disease. Blood 2011, 118(24):6461-6464. 10.1182/blood-2011-06-363457, 3236127, 21828132.
25. Leistner DM, Fischer-Rasokat U, Honold J, Seeger FH, Schachinger V, Lehmann R, Martin H, Burck I, Urbich C, Dimmeler S, Zeiher AM, Assmus B. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol 2011, 100(10):925-934. 10.1007/s00392-011-0327-y, 21633921.
26. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 2009, 457(7231):892-895. 10.1038/nature07679, 2661201, 19182774.
27. Ohtani K, Vlachojannis GJ, Koyanagi M, Boeckel JN, Urbich C, Farcas R, Bonig H, Marquez VE, Zeiher AM, Dimmeler S. Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells. Circ Res 2011, 109(11):1219-1229. 10.1161/CIRCRESAHA.111.247304, 21980126.
28. Spinetti G, Fortunato O, Caporali A, Shantikumar S, Marchetti M, Meloni M, Descamps B, Floris I, Sangalli E, Vono R, Faglia E, Specchia C, Pintus G, Madeddu P, Emanueli C. MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res 2013, 112(2):335-346. 10.1161/CIRCRESAHA.111.300418, 3616367, 23233752.
29. Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, Huang PH, Liu PL, Chen YL, Chen JW. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007, 56(6):1559-1568. 10.2337/db06-1103, 17389326.
30. Ho JC, Lai WH, Li MF, Au KW, Yip MC, Wong NL, Ng ES, Lam FF, Siu CW, Tse HF. Reversal of endothelial progenitor cell dysfunction in patients with type 2 diabetes using a conditioned medium of human embryonic stem cell-derived endothelial cells. Diabetes Metab Res Rev 2012, 28(5):462-473. 10.1002/dmrr.2304, 22492468.
31. Fadini GP, Avogaro A. Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. Atherosclerosis 2013, 229(1):23-29. 10.1016/j.atherosclerosis.2013.04.007, 23643052.
32. Fiorina P, Pietramaggiori G, Scherer SS, Jurewicz M, Mathews JC, Vergani A, Thomas G, Orsenigo E, Staudacher C, La Rosa S, Capella C, Carothers A, Zerwes HG, Luzi L, Abdi R, Orgill DP. The mobilization and effect of endogenous bone marrow progenitor cells in diabetic wound healing. Cell Transplant 2010, 19(11):1369-1381. 10.3727/096368910X514288, 20977829.
33. Marfella R, Sasso FC, Rizzo MR, Paolisso P, Barbieri M, Padovano V, Carbonara O, Gualdiero P, Petronella P, Ferraraccio F, Petrella A, Canonico R, Campitiello F, Della Corte A, Paolisso G, Canonico S. Dipeptidyl peptidase 4 inhibition may facilitate healing of chronic foot ulcers in patients with type 2 diabetes. Exp Diabetes Res 2012, 2012:892706. 3503302, 23197976.
34. Goncalves A, Leal E, Paiva A, Teixeira Lemos E, Teixeira F, Ribeiro CF, Reis F, Ambrosio AF, Fernandes R. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 2012, 14(5):454-463. 10.1111/j.1463-1326.2011.01548.x, 22151893.
35. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol 2012, 11:6. 10.1186/1475-2840-11-6, 3277488, 22248301.
36. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369(14):1317-1326. 10.1056/NEJMoa1307684, 23992601.
37. Petrelli A, Maestroni A, Fadini GP, Belloni D, Venturini M, Albiero M, Kleffel S, Mfarrej BG, Maschio AD, Maffi P, Avogaro A, Ferrero E, Zerbini G, Secchi A, Fiorina P. Improved function of circulating angiogenic cells is evident in type 1 diabetic islet-transplanted patients. Am J Transplant 2010, 10(12):2690-2700. 10.1111/j.1600-6143.2010.03309.x, 21114646.
38. Petrelli A, Di Fenza R, Carvello M, Gatti F, Secchi A, Fiorina P. Strategies to reverse endothelial progenitor cell dysfunction in diabetes. Exp Diabetes Res 2012, 2012:471823. 3296202, 22474422.